Immunosuppressants - Asia

Asia

The Immunosuppressants market in Asia is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$7.51bn by 2024.
Furthermore, it is anticipated that the market will display a steady annual growth rate (CAGR 2024-2028) of 16.11%, resulting in a market volume of US$13.65bn by 2028.
When compared globally, United States is expected to generate the highest revenue in the Immunosuppressants market, with a projected value of US$33,610.00m in 2024.
In Asia, the demand for immunosuppressants is rapidly increasing due to the rising prevalence of autoimmune diseases in the region.

Key regions: Italy, Canada, Australia, France, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Asia has been steadily increasing over the past decade.

Customer preferences: Patients suffering from autoimmune diseases, organ transplants, and other conditions that require immunosuppressants are the primary customers for these drugs. In Asia, the demand for these drugs has been driven by an increasing prevalence of autoimmune diseases and organ transplant surgeries.

Trends in the market: China and India are the largest markets for immunosuppressants in Asia, with a significant portion of the population suffering from autoimmune diseases. The market for immunosuppressants has been growing rapidly in these countries due to the increasing number of organ transplant surgeries. Japan is also a significant market for immunosuppressants due to its aging population and high prevalence of autoimmune diseases.

Local special circumstances: In China, the government has been encouraging organ donation and transplant surgeries, which has led to an increase in demand for immunosuppressants. The Chinese government has also been investing in the development of domestic pharmaceutical companies to reduce reliance on imports. In India, the market for immunosuppressants is highly competitive, with several domestic and international players vying for market share.

Underlying macroeconomic factors: The growth in the immunosuppressants market in Asia is driven by several underlying macroeconomic factors. The increasing prevalence of autoimmune diseases and organ transplant surgeries is a result of changing lifestyles, rising pollution levels, and aging populations. The growing middle class in Asia has also led to an increase in healthcare spending, driving demand for immunosuppressants. The increasing focus on healthcare infrastructure and government initiatives to improve access to healthcare in developing countries in Asia have also contributed to the growth of the immunosuppressants market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.